Jooyoung Chang, He‐Zhou Huang, Mei Yuan, Yuan Zhou, Dan Liu, Ke‐Bin Zhan, Ling‐Qiang Zhu
Chronic alcohol consumption is increasingly recognized as a risk factor for Alzheimer's disease (AD), contributing to cognitive decline through multiple biological pathways. Excessive alcohol intake accelerates neurodegeneration by impairing the brain's ability to clear toxic proteins, disrupting neurotransmitter balance, and exacerbating inflammation and oxidative stress. These effects collectively weaken neuronal resilience, making the brain more vulnerable to AD-related damage. Emerging therapeutic strategies focus on mitigating alcohol-induced harm through neuroprotective drugs, inflammation-targeting treatments, and neurotransmitter modulators. Lifestyle-based interventions, including early abstinence, cognitive training, and precision nutrition, also show promise in reducing risk and slowing disease progression. Future research should prioritize personalized treatment approaches and novel drug delivery methods to improve outcomes for individuals affected by both conditions.